Haisco expanded its newco strategy via a Sentivera transaction worth more than $1.5 billion, according to reporting. The deal created Sentivera around an undisclosed preclinical immunology asset, backed by a launch involving Arch Venture Partners and Population Health Partners. The structure suggests an effort to build a dedicated oral-therapy competitor in type 2 inflammatory diseases, a crowded but high-value space where route-to-market and formulation can differentiate late development. For Haisco, the partnership approach signals continued portfolio modularity: moving early immunology assets into venture-backed entities aimed at faster execution and potential partnering leverage. For competitors, Sentivera’s emergence adds another platform claimant to oral type 2 inflammatory disease pipelines, where Phase 1/2 differentiation and safety/tolerability will shape whether clinical programs can capture meaningful market share.